Welcome to our dedicated page for ZimVie news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZimVie stock.
ZimVie Inc. (Nasdaq: ZIMV) is a leading global life sciences company specializing in the dental and spine markets. Formed in March 2022 as an independent spin-off from Zimmer Biomet, ZimVie focuses on developing, manufacturing, and delivering a diverse portfolio of innovative products designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures.
Company Segments:
- Spine Products Segment: ZimVie offers an array of spine solutions, including implants, surgical tools, and bone graft substitutes. Significant advancements include the launch of the 4.5mm Mobi-C Cervical Disc, which provides pain relief and motion preservation for cervical disc degeneration.
- Dental Products Segment: The company delivers comprehensive dental solutions, including implants and digital care management systems. ZimVie is committed to driving peri-implant health and immediacy through its innovative dental product lines.
Recent Achievements:
- In October 2023, ZimVie celebrated the first U.S. implantation of its 4.5mm Mobi-C implant.
- In December 2023, the company received FDA clearance for its Vital™ Spinal Fixation System, designed for use with Brainlab Spine & Trauma Navigation.
Current Projects:
- ZimVie is actively co-marketing Brainlab Spine & Trauma Navigation alongside its Vital and Virage product lines, with plans to expand further in 2024.
- The company is also focused on the strategic sale of its spine business to H.I.G. Capital, expected to close in the first half of 2024. This move aims to streamline operations and sharpen focus on the dental sector.
Financial Health:
ZimVie continues to navigate its financial landscape with strategic initiatives like debt reduction and reallocation of resources to higher-growth dental markets. The company has paid down significant debt while maintaining a robust portfolio of products supported by extensive clinical evidence.
Partnerships:
ZimVie collaborates with leading organizations like Brainlab to enhance its product offerings, ensuring cutting-edge solutions in spine and dental care. These partnerships enable ZimVie to remain at the forefront of technological advancements in the medical device industry.
ZimVie Inc. (ZIMV) reported Q3 2024 financial results with third-party net sales of $103.2 million, showing a 2.0% decrease from Q3 2023. The company posted a net loss of $(3.0) million, improving from a $(10.2) million loss in the previous year. Adjusted EBITDA reached $13.1 million with a 12.7% margin, up 110 basis points year-over-year. The company reported GAAP diluted EPS of $(0.11) and adjusted diluted EPS of $0.12. ZimVie updated its full-year 2024 guidance, projecting net sales between $450M to $455M and adjusted EBITDA between $60M to $62M.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, November 12, 2024, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.
Interested parties can access both the live webcast and an archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its third quarter 2024 financial results after market close on Wednesday, October 30, 2024. The company will host a conference call to discuss the results, beginning at 4:30 p.m. Eastern Time on the same day.
Interested parties can register for the conference call online. It is recommended to register more than 15 minutes before the call starts. For those unable to attend the live call, a replay of the webcast will be made available on the company's investor relations website at investor.zimvie.com.
ZimVie Inc. (ZIMV) reported Q2 2024 financial results for its continuing operations in the dental market. Key highlights include:
- Third party net sales of $116.8 million, down 1.5% year-over-year
- Net loss of $(9.6) million, with a net loss margin of 8.2%
- Adjusted EBITDA of $16.1 million, with a 13.8% margin
- Reduced debt to $235.1 million
- Cash balance of $78.6 million
The company reaffirmed its full-year 2024 guidance, projecting net sales of $450-$460 million, adjusted EBITDA of $60-$65 million, and adjusted EPS of $0.55-$0.70. CEO Vafa Jamali highlighted progress in customer engagement, product innovation, and operational improvements.
ZimVie Inc. (Nasdaq: ZIMV) has released RealGUIDE® 5.4, an update to its dental implant software suite. This latest version introduces new features designed to enhance provider efficiency and cost savings. Key improvements include:
1. One-click nerve detection and automated bone and tooth segmentation for faster complex case planning and improved risk management.
2. New restorative design workflows to meet evolving clinic and dental laboratory needs.
3. Amplified CAD workflows for creating attractive implant dentistry designs.
4. Automated 'split-bar' toolset for efficient creation of complex multi-material prostheses.
5. Cloud-based design libraries for improved accessibility.
The update aims to make guided surgery the standard for all implant cases, potentially increasing implant dentistry adoption.
ZimVie Inc. (Nasdaq: ZIMV) has announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio, following FDA 510(k) clearance. This launch expands ZimVie's end-to-end prosthetic offerings in the dental market. The GenTek portfolio, first introduced in Europe in 2019, includes Ti-Bases, pre-milled abutment blanks, screws, instruments, and ancillary products for digitally driven CAD/CAM restorations.
Designed to mate with ZimVie implant systems, GenTek components ensure a perfect fit and tight seal for long-term aesthetic and functional restorations. The company anticipates strong demand in the U.S. market, following the product's success in Europe.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its second quarter 2024 financial results after market close on Thursday, August 1, 2024. The company management will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested parties can register for the call online, with registration recommended more than 15 minutes before the call starts. A replay of the webcast will be available on the company's investor relations website.
On May 16, 2024, ZimVie, a global leader in the dental market, announced its participation in two upcoming investor conferences. The company will present at the Stifel 2024 Jaws & Paws Conference on May 30, 2024, at 11:30 a.m. Eastern Time, and at the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024, at 3:20 p.m. Eastern Time. Interested parties can access a live webcast of these presentations through the 'Investors' section on ZimVie's website.
ZimVie Inc. (Nasdaq: ZIMV) reported third party net sales of $118.2 million, a net loss of ($11.5) million, and an adjusted EBITDA of $12.5 million for the first quarter of 2024. The company completed the sale of its spine business for $375 million, repaid $275 million of debt, and is now focusing on its dental market leadership.
FAQ
What is the current stock price of ZimVie (ZIMV)?
What is the market cap of ZimVie (ZIMV)?
What does ZimVie Inc. specialize in?
When was ZimVie founded?
What are the two main operating segments of ZimVie?
What is the Mobi-C Cervical Disc?
What recent FDA clearance did ZimVie receive?
Who is ZimVie selling its spine business to?
How does ZimVie plan to use the proceeds from the spine business sale?
What are some of ZimVie's partnerships?
Where is ZimVie headquartered?
What markets does ZimVie serve?
